Cargando…
HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model
Multi-drug delivery systems, which may be promising solution to overcome obstacles, have limited the clinical success of multi-drug combination therapies to treat cancer. To this end, we used three different anticancer agents, Cu(BpT)Br, NAMI-A, and doxorubicin (DOX), to build human serum albumin (H...
Autores principales: | Gou, Yi, Zhang, Zhenlei, Li, Dongyang, Zhao, Lei, Cai, Meiling, Sun, Zhewen, Li, Yongping, Zhang, Yao, Khan, Hamid, Sun, Hongbing, Wang, Tao, Liang, Hong, Yang, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058715/ https://www.ncbi.nlm.nih.gov/pubmed/29350051 http://dx.doi.org/10.1080/10717544.2018.1428245 |
Ejemplares similares
-
Effect of Pullulan Nanoparticle Surface Charges on HSA Complexation and Drug Release Behavior of HSA-Bound Nanoparticles
por: Tao, Xiaojun, et al.
Publicado: (2012) -
hsa_circ_0072389, hsa_circ_0072386, hsa_circ_0008621, hsa_circ_0072387, and hsa_circ_0072391 aggravate glioma via miR-338-5p/IKBIP
por: Liang, Jian, et al.
Publicado: (2021) -
Pullulan-Based Nanoparticle-HSA Complex Formation and Drug Release Influenced by Surface Charge
por: Yuan, Liming, et al.
Publicado: (2018) -
Hsa_circ_0128846 promotes tumorigenesis of colorectal cancer by sponging hsa‐miR‐1184 and releasing AJUBA and inactivating Hippo/YAP signalling
por: Wang, Xu, et al.
Publicado: (2020) -
Prognostic value of hsa-mir-299 and hsa-mir-7706 in hepatocellular carcinoma
por: Wang, Fenglin, et al.
Publicado: (2018)